- Mediterrania Capital Partners has announced its acquisition of a stake in Laprophan, one of Morocco’s leading pharmaceutical companies
- The acquisition was through its fund MC IV alongside DEG, Proparco, and FMO and this investment aims to boost Lapophan’s growth
- This partnership will also help reinforce Laprophan’s offering and improve public health in Morocco as well as its international footprint
Morocco – Mediterrania Capital Partners, a Private Equity firm focused on growth investments for SMEs and mid-cap companies in North Africa and Sub-Saharan countries, is pleased to announce its acquisition of a stake in Laprophan (www.laprophan.com) – one of the leading pharmaceutical companies in Morocco, through its fund MC IV, alongside Germany’s development finance institution DEG, Proparco, and FMO.
Founded in 1949 by Abderrahim Bennis, Laprophan is a pioneering pharmaceutical company and nowadays stands out as one of the undisputed leaders in the manufacturing, distribution, import, and export of pharmaceutical products in Morocco.
The company distributes its own branded products and imported finished products from large international laboratories, providing patients and healthcare professionals with a wide range of medical drugs covering over 40 specialties.
Laprophan also exports products to more than 30 countries across Africa and the Middle East and is an internationally renowned brand in the region.
Through its investment, the consortium aims to support Laprophan’s growth and expansion plans triggered by the recent generalisation of Morocco’s compulsory health insurance scheme (“AMO”), which has doubled the number of beneficiaries in the last 12 months to reach 22 million people, and the rise of demand for generic drugs in Morocco and Sub-Saharan markets.
Subscribe to our weekly newsletter and get industry reports and deals happening in Africa.
Commenting on the transaction, Albert Alsina, Founder, and CEO of Mediterrania Capital Partners, said:
“We thank our longstanding partners DEG, Proparco, and FMO for their trust and financial support which have been crucial in enabling this important transaction. We’re very excited to join forces and work with Laprophan’s management to reach the company’s next stage of development.”
Hatim Ben Ahmed, Managing Partner at Mediterrania Capital, added:
“Laprophan, with its outstanding leadership team, strong focus on innovation, and solid commitment to make medicines more accessible across Africa and the Middle East, is the ideal investment opportunity from both a value creation and impact perspective.”
Farid Bennis, CEO of Laprophan, added:
“We are very happy to have Mediterrania Capital Partners and its co-investors with us to write a new chapter in Laprophan’s development plan together. This partnership will greatly help reinforce our offering and so improve public health as well as our international footprint.”
Laprophan was advised by Ascent Capital Partners and GBL, its financial and legal advisors, respectively. Mediterrania Capital Partners and the co-investors obtained legal advice from ASAFO & Co.
Mediterrania Capital Partners has been present in Morocco since 2013 with investments in Akdital Holding, Cash Plus, C.E.C.I., Dislog Industries, Indigo Company, MedTech, TGCC, and Université Privée de Marrakech.
ALSO READ: Tamela Capital Partners in South Africa Pharma Deal
Subscribe to our weekly newsletter and get industry reports and deals happening in Africa.